BBIO logo

BBIO BridgeBio Pharma Inc

$64.82
$0.75
(1.14%)
Today
60

Bullish Sentiment

How do you feel about BBIO?

Loading...
Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence
ExxonMobil, ADP and Cadence highlight today's analyst reports, with growth drivers, market risks and strategic moves shaping their outlooks.
Zacks
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
Zacks
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
Zacks
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Zacks
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Zacks
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.
Stocktwits
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
Zacks
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
Zacks